SPM 5185

Drug Profile

SPM 5185

Latest Information Update: 20 May 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schwarz Pharma
  • Developer Thomas Jefferson University
  • Class Anti-ischaemics; Antiplatelets; Heart failure therapies; Organic nitrates; Vasodilators
  • Mechanism of Action Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Heart failure; Myocardial ischaemia

Most Recent Events

  • 20 May 1996 An in vitro study has been added to the pharmacodynamics section for Ischaemic Heart Disease .
  • 29 Mar 1996 Discontinued-Preclinical for Heart failure in USA (Unknown route)
  • 29 Mar 1996 Discontinued-Preclinical for Myocardial ischaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top